The company discontinued developing emugrobart after two studies showed the drug didn’t achieve intended outcomes.
It provides a surge of moisture and a natural glow ...
At AD/PD 2026, Roche announced that patients treated with prasinezumab for five years demonstrated a sustained slowing of ...
Roche Diagnostics Africa has launched Integration Accelerated, a new initiative that uses existing lab infrastructure to ...
Medical Device Network on MSN
Roche unveils cobas MPX-E assay for HIV and hepatitis viruses
The assay is developed to address current demands of laboratories.
In a letter to European patients, Roche said its decision to end development of “emugrobart” was based on the drug “not ...
It’s looking like Roche may not receive an on-time FDA decision for the subcutaneous version of its cancer immunotherapy Tecentriq. The FDA was supposed to dole out a verdict on subcutaneous Tecentriq ...
Roche announced today the U.S. Food and Drug Administration (FDA) 510(k) clearance of its newest analytical units – the ...
La Roche-Posay is a New York-based brand, but their roots are in France. The brand was founded in a French town of the same name in 1975, and it still manufactures products there today. To understand ...
Roche (RHHBF) stock is in focus as the company halts mid-stage trials for emugrobart in rare neuromuscular diseases but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results